The Precision Peptide Company Inc. Signs Agreement with U.S.-Based 503A Sterile Compounding Pharmacy - Peptides to be 100% Compounded in the United States

Highlights Executed compounding agreement with a U.S.-based 503A sterile compounding pharmacy partner Compounding activities under the agreement expected to commence on Monday, June 1, 2026 All peptides under the agreement to be 100% compounded in the United States Designed to support prescription-based peptide preparation and fulfillment, including BPC-157 Up to approximately 25,000 prescriptions per day in fulfillment capacity available under the agreement, with reach across all U.S. states Strengthens the Company's U.S. supply chain and regulatory footprint Comes amid recent U.S. regulatory developments advancing clarity around peptide substances, including the FDA's referral of multiple peptides to the Pharmacy Compounding Advisory Committee (PCAC) for evidence-based evaluation Vancouver, British Columbia--(Newsfile Corp. - June 2, 2026) - The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "BPC"), a publicly traded wellness company focused on advanced peptide formulations and delivery systems, today announces that it has entered into a compounding agreement (the "Compounding Agreement") with a U.S.-based 503A sterile compounding pharmacy (the "Compounding Partner") for the future prescription-based preparation and fulfillment of the Company's peptide products, including BPC-157. Under the Compounding Agreement, the Compounding Partner will provide the Company with access to large-scale pharmaceutical compounding infrastructure with the capacity to fulfill up to approximately 25,000 prescriptions per day across all U.S. states.